Kriya Therapeutics Names Dr. Greg Di Russo as Chief Medical Officer
Kriya Therapeutics, Inc., a key player in the clinical-stage biopharmaceutical arena, recently announced the appointment of Greg Di Russo, MD, as its new Chief Medical Officer. Dr. Di Russo will drive the company's medical operations and clinical strategy as Kriya continues to push innovative gene therapies forward.
Leadership Transition at Kriya
The leadership change comes at a pivotal moment for Kriya, which is dedicated to developing life-altering gene therapies aimed at conditions that impact millions globally. Dr. Shankar Ramaswamy, Co-Founder and CEO of Kriya, expressed enthusiasm regarding Dr. Di Russo's extensive experience. He stated, "Greg is a phenomenal leader with a track record of successfully developing complex products across diverse therapeutic areas. We look forward to his leadership as we scale the organization to tackle multiple chronic diseases of high unmet need and advance our mission of making gene therapy a cornerstone of mainstream medicine."
Dr. Di Russo's Background and Experience
Dr. Di Russo comes to Kriya with over two decades of diverse experience in clinical practice and the pharmaceutical industry. He has been involved in the development of various gene therapy and biologic products, gaining invaluable expertise in managing clinical trials and drug safety protocols. This rich background in both adult and pediatric medicine positions him as a strategic leader for overseeing Kriya's medical organization.
Insights on the Potential of Gene Therapy
Expressing his excitement about joining Kriya, Dr. Di Russo remarked, "I am delighted to be joining Kriya at this time, when advances in gene therapy have the potential to deliver transformative treatments to broad populations of patients with serious diseases. Kriya has the potential to leverage state-of-the-art science and technology to realize this potential with a collaborative, patient-centric approach." This focus on innovation and patient care is central to Kriya’s mission.
Key Achievements at Pfizer and Other Contributions
Prior to his role at Kriya, Dr. Di Russo served as the Development Head for Non-Malignant Hematology at Pfizer. In this capacity, he significantly contributed to the development of treatments for hemophilia and sickle cell disease, managing the gene therapies BEQVEZ™ and giroctocogene fitelparvovec, among other projects. His experience extends to notable roles at CSL Behring and Bristol-Meyers Squibb, where he helped advance therapeutic solutions.
Educational Background
Dr. Di Russo earned his medical degree from Sidney Kimmel Medical College, complemented by an undergraduate degree from Princeton University. His education and professional experience reflect a strong commitment to advancing healthcare.
About Kriya Therapeutics
Kriya Therapeutics operates with a clear mission: to revolutionize medicine and alleviate human suffering through advanced therapeutics. The company is committed to developing gene therapies targeting chronic diseases that affect populations around the world. Kriya boasts a robust pipeline of transformational medicines across various therapeutic areas, including ophthalmology, metabolic diseases, and neurology, underpinned by a proprietary manufacturing and engineering platform.
For more details about Kriya's initiatives and corporate philosophy, you can visit their official website and connect on LinkedIn and Twitter to stay updated on their progress.
Frequently Asked Questions
Who is the new Chief Medical Officer of Kriya Therapeutics?
Greg Di Russo, MD, has been appointed as the Chief Medical Officer of Kriya Therapeutics.
What is Dr. Di Russo's previous experience?
Dr. Di Russo previously served at Pfizer as the Development Head for Non-Malignant Hematology and has significant experience in gene therapy development.
What is the mission of Kriya Therapeutics?
Kriya Therapeutics aims to revolutionize medicine and eliminate human suffering through innovative gene therapies.
What areas does Kriya's pipeline target?
Kriya's pipeline includes therapies in ophthalmology, metabolic diseases, and neurology.
How can I stay updated on Kriya's developments?
You can follow Kriya Therapeutics on their official website, LinkedIn, and Twitter for the latest news and updates.
